search

All clinical trials

Results 8551-8560 of 470744

Focal Vibration on the Performance of Amateur Athletes

Vibration; ExposureSports Physical Therapy

Focal vibration is an adjustable instrument, which has the ability to apply vibration to a specific point at different hertz, powers and rhythms. The use of general or focused vibration is not new in the rehabilitation or sports field. Vibration is intended to stimulate neuromuscular uses to produce involuntary and additional contractions of muscle tissue, indirectly causing an increase in strength or muscle mass , improved fall prevention, mobility and bone consolidation. This type of device has been used both in athletes and in patients with chronic diseases or in intensive care units. There are studies that use vibration in critically ill patients because it is a safe and feasible intervention for dependent patients. One of the advantages of focal vibration is that it can be used in both unloading and loading, which allows a wide range of adaptation to each patient, even simultaneously during a training activity. The aim of the present study is to evaluate the effectiveness of a focal vibration treatment on strength, jumping and running speed in national federated athletes who perform sprinting and jumping in their sports practice. A sample will be recruited during the months of April to September, estimating a sample of 70 total subjects (35 subjects in the vibration group and 35 subjects in the vibration placebo group). Patients will receive a single treatment and assessments will be performed on the same day. The focal vibration group will receive a 30-minute quadriceps intervention. 3 channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The vibration program configuration will be in an automatic mode of 10 seconds of vibration 3 seconds of rest to avoid mechanoreceptor coupling. The frequency used will be between 60 Hz to 150 Hz with a power of 80%. The placebo group will perform the same treatment as the intervention group but without the focal vibration head contacting the skin (placebo). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin as shown in previous studies. A V-Plus machine (Wintecare S.A.) will be used for the vibration treatment. For the assessment measurements, a surface electromyograph, a force measurement dynamometer, the MyJump2 application for jump assessment and two photoelectric cells for sprint measurement will be used.

Recruiting7 enrollment criteria

Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS...

Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia

This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.

Recruiting58 enrollment criteria

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo...

Nonsegmental Vitiligo With Genital Involvement

An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas identified for treatment at baseline regardless of whether the area begins to improve or fully repigment.

Recruiting17 enrollment criteria

RCT of an Integrated Digital Intervention for Alcohol Use Disorder

Alcohol Use Disorder

This study is a two-arm randomized clinical trial comparing the Quit Genius intervention for alcohol use disorder (QG-A) to usual care (TAU), comprising medical management of alcohol use disorders with pharmacotherapy. Participants (N=300) will be randomly assigned to either QG-A or TAU, and will be assessed at baseline, monthly throughout the 6-month intervention phase and at 3 and 6 months post-treatment, to investigate the impact of QG-A, relative to TAU on alcohol use, psychological symptoms, and health service utilization. The primary aim of the study is to evaluate the efficacy of QG-A, relative to TAU in reducing alcohol use and associated mental health and functional outcomes. A secondary aim is to examine the cost-effectiveness of QG-A, including cost savings and impact on productivity.

Recruiting18 enrollment criteria

Does Cell-U-Light Apparel Improve Cellulite

Cellulite

This trial is arranged in 3 stages, lasting 8 weeks overall, designed to assess the before, during and after effects of the low-compression apparel with its integrated, variably raised, ink-polymer pads. The study will recruit 21 (otherwise healthy) participants who are affected by cellulite. Volunteers will be selected in order to equally fill the 3 different grades of cellulite (7 volunteers of each grade (1, 2 & 3) - as Grade 0 is no evidence of cellulite, this category need not be included). Each volunteer will be 'sized' according to standard apparel sizing charts (as used by the manufacturer of the cycle shorts); Small (S), Medium (M), Large (L) and Extra Large (XL). All participants will follow the same 3 stage sequence, which will involve a total of 9 short visits to The Whiteley Clinic, each lasting approximately 30 minutes. Upon completion of these visits, participants will each be offered £90 to subsidise their cost of travel - they will also be permitted to keep the low-compression apparel following the study. During each appointment, several measurements and assessment will be made: Standard demographics, weight, height, and any changes to dietary or exercise regimens over the trial period. Subjective assessment of the cellulite by the participant. Objective assessment and grading using the grading system described by Nunberger and Muller by the investigators Images of their cellulite-affected areas will be taken (this may include an area over the buttocks and an area over the thighs), using a high-resolution medical imaging (camera) system (Vectra H2 (https://www.canfieldsci.com/imaging-systems/vectra-h2-3d-imaging-system/)), to be independently assessed by Canfield Consultants and to be graded by a 'panel' of clinicians for objective classifications. Assessment of local lymphatic collections in the skin using a handheld lymph scanner to assess lymph accumulation (Delfin Lymphscanner, Delfin Technologies Ltd https://hadhealth.com/lymphscanner). During stage 2 only, participant assessment as to ease of donning and doffing the product, and comfort of wearing it.

Recruiting13 enrollment criteria

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive...

Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: Learn how well the combination of tucatinib and Doxil works Learn more about the side effects of the combination of tucatinib and Doxil

Recruiting54 enrollment criteria

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder...

Generalized Anxiety Disorder

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Recruiting14 enrollment criteria

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality...

Myocardial InfarctionAcute

Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention FCM or placebo arm. Time of observation 12 months [12 main study + 3 years follow up in substudy B]. Primary Study Objective: Primary: Evaluation of the effect of i.v. FCM treatment compared with placebo on the risk of cardiovascular (CV) death, the risk of heart failure events (HFE*) (number of events and time to first event) during the 12-month follow-up and the change in quality of life (QoL) assessed using EQ-5D during the 8-month follow-up in patients with recent AMI and ID (with an implementation of a win ratio approach in a hierarchical descending order). *HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms).

Recruiting28 enrollment criteria

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Breast Cancer Metastatic

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Recruiting14 enrollment criteria

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Breast Cancer Metastatic

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Recruiting15 enrollment criteria
1...855856857...47075